No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
TNGX250117P7500
- 0.00
- 0.000.00%
15min DelayClose Dec 26 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-140.38%PremiumJan 17, 2025Expiry Date4.38Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.86Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Cantor Fitzgerald Reiterates Overweight on Tango Therapeuticsto Overweight
Tango Therapeutics Analyst Ratings
Express News | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics Granted FDA Orphan Designation Status For "Small Molecule Inhibitor of PRMT5 (Protein Arginine Methyl Transferase 5)" Treatment Of Pancreatic Cancer
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference